Clinical Trials | October 22, 2025
AbbVie's Rinvoq beats Humira in key arthritis trial
The SELECT-SWITCH study, first head-to-head Phase 3b/4 trial, compared switching to Rinvoq versus switching to another TNF inhibitor
The SELECT-SWITCH study, first head-to-head Phase 3b/4 trial, compared switching to Rinvoq versus switching to another TNF inhibitor
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
Celecoxib is a nonsteroidal anti-inflammatory drug
Lupin and Zentiva sign license and supply agreement for commercializing Certolizumab
Celecoxib Capsules approval complements Strides’ existing products to serve a broader patient base
Ibuprofen and famotidine combination is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis
Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases
Dr. Reddy's had previously received the EU GMP certificate for its Rituximab drug substance
Shilpa Biologicals has developed high concentration adalimumab (100 mg/mL)
The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio
Subscribe To Our Newsletter & Stay Updated
